Shares of Aligos Therapeutics rose 7.6% in pre-market trading on Wednesday after the company reported second-quarter financial results that beat analyst expectations and provided updates on its clinical pipeline.
The biotech firm, which focuses on therapies for chronic hepatitis B, posted a narrower net loss than projected for the three months ended June 30, 2026. Earnings per share also exceeded consensus estimates, contributing to the positive sentiment. Aligos' stock reached $6.55 in pre-market trading, though it remains well below its 52-week high of $13.69.
The company also highlighted a licensing agreement for Greater China related to pevifoscorvir sódico, which provided non-dilutive funding. This strengthened Aligos' balance sheet without issuing new shares. Separately, the firm announced the completion of full patient recruitment for its Phase 2 B-SUPREME study, evaluating pevifoscorvir sódico in patients with chronic hepatitis B virus infection.
The gains came as major U.S. stock indices declined, with the NASDAQ falling 0.6%, the S&P 500 down 0.2%, and the Dow Jones easing 0.1%. The outperformance reflected company-specific developments rather than broader market trends.
Aligos' shares have gained approximately 7% in pre-market trading, following the release of its Q2 2026 results at the beginning of August 2026.
